glp 1 drugs shortage FDA Ends Compounding of GLP-1 as Shortages Improve, The U.S. Food and Drug Administration (FDA) has announced the end of the for GLP-1 weight loss drugs like Ozempic, leading to the What Changed? The FDA's Clarification

The two drugs are also competing head to head in obesity, where Novo Nordisk sells its drug as Wegovy and Lilly's is called Zepbound

Rotate injection sites - abdomen, thigh, and the back of the upper arm are common subQ sites for all three compounds

Retailers have also begun adjusting to meet the needs of these customers, including changing up ready meal offerings to increase protein and vegetables, stocking more on-the-go protein enhanced beverages, and highlighting products to help with side effects (e.g., gum to help with nausea) (Kendall, 2025

Szkudlarek HJ, Desai SJ, Renard J, Pereira B, Norris C, Jobson CEL, et al

La concentracin final se determina por el volumen de diluyente en relacin con los miligramos del vial, lo que permite dosificar volmenes pequeos y reproducibles dado el carcter potente y acumulativo del compuesto